A Novel Use of Liraglutide: Induction of Partial Remission in Ulcerative Colitis and Ankylosing Spondylitis

Lourie Jeffrey

doi:10.23937/2378-3656/1410281

Lourie Jeffrey

Open Access

PDF Available

https://doi.org/10.23937/2378-3656/1410281

Copy DOI

Export

Save

Cite

Journal: Clinical Medical Reviews and Case Reports	Publication Date: Aug 29, 2019
Citations: 4	License type: cc-by

Abstract
Highlights/Summary
Full-Text PDF
Similar Papers

Abstract

Listen

Ulcerative colitis and ankylosing spondylitis treatment options are limited to a few classes of medications at this time. Those options provide improvement for some patients, but leaves many with ongoing, unremitting symptoms. We report a case of ulcerative colitis (UC) with comorbid ankylosing spondylitis (AS), in which administration of a daily subcutaneous liraglutide, an exogenous Glucagon-like Peptide-1 receptor agonist (GLP-1RA), led to symptomatic remission of UC and significant improvement in AS symptoms.

Highlights

We present a case of symptomatic remission of ulcerative colitis (UC) and significant symptomatic improvement in ankylosing spondylitis (AS) after initiation of daily subcutaneous liraglutide.Glucagon-like Peptide-1 (GLP-1) receptors (GLP-1R) are involved multiple areas of biological activity, primarily involving the GI tract and regulation of blood glucose levels
We present a case of symptomatic remission of UC and significant symptomatic improvement in AS after initiation of daily subcutaneous liraglutide
GLP-1 receptors (GLP-1R) signaling in the intestine and subsequent up-regulation of intestinal epithelial lymphocytes has been established as part of the inflammatory response pathway [6,7], and enteroendocrine L cells increase their secretion of GLP-1 in response to systemic inflammation [8]

Summary

Introduction

We present a case of symptomatic remission of UC and significant symptomatic improvement in AS after initiation of daily subcutaneous liraglutide. Subcutaneous liraglutide was initiated and slowly titrated for treatment of obesity He made no dietary changes (other than the addition of fiber) nor modified activities or lifestyle over the course of this treatment. We have pre-treatment colonoscopy data confirming active disease, but no post-treatment data He reported significant improvement after 3 days of subcutaneous liraglutide 0.6 mg, and once titrated to 1.8 mg daily reported full remission. Symptoms were improved with the exception of fatigue He reported remission of UC to the point of mild constipation, which he states has never been an issue for him in the past. This was relieved with the addition of a regimen of oral fiber supplementation and increased hydration Otherwise he reported no side effects or issues with the medication (except for early-treatment mild nausea, which subsided within 3-4 days of each dose increase)

Discussion

Conclusions